无导线与经静脉单腔心室起搏的成本效果：一项法国倾向性加权真实世界研究

数据集获取（Figshare）

• 源站标题：Cost-effectiveness of leadless versus transvenous single-chamber ventricular pacing: a propensity-weighted real-world study in France
• DOI：10.6084/m9.figshare.31942377.v1
• 发布日期：2026-04-06
• 文件数：3 个
• 文件总体积：383.74 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Cost-effectiveness_of_leadless_versus_transvenous_single-chamber_ventricular_pacing_a_propensity-weighted_real-world_study_in_France/31942377

命令行下载

curl -L -o "iann_a_2652657_sm3408.docx" "https://ndownloader.figshare.com/files/63473304"
curl -L -o "iann_a_2652657_sm3407.tif" "https://ndownloader.figshare.com/files/63473307"
curl -L -o "iann_a_2652657_sm3406.docx" "https://ndownloader.figshare.com/files/63473310"

文件清单

• iann_a_2652657_sm3408.docx（86.45 KB）
• iann_a_2652657_sm3407.tif（282.05 KB）
• iann_a_2652657_sm3406.docx（15.24 KB）

文件总体积 383.74 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Leadless pacemakers (LP) have emerged as an alternative to conventional transvenous single-lead ventricular pacemakers (SLP), with expanding indications beyond initially selected patients. This study evaluated the clinical and economic outcomes of LP compared with SLP in eligible patients from a real-world French hospital cohort.
We conducted a retrospective, propensity-weighted cost-effectiveness analysis from a hospital-based perspective, including all patients who underwent first LP or SLP implantation between 2016 and 2020 at our center. Patients with contraindications or high risk of device failure or infection were excluded. Four-year costs and life-years were used to estimate the incremental cost-effectiveness ratio (ICER). Cost-effectiveness acceptability curves (CEACs) were derived from the bootstrapped distribution of net monetary benefits. Sensitivity analyses explored cost drivers and robustness.
A total of 352 patients were included (104 LP, 248 SLP). After weighting, LP was associated with shorter procedure duration (52 vs 80 min; p p = 0.007). Major clinical events occurred in 25.2% (LP) vs 33.8% (SLP; p = 0.17). Although implantation costs were higher for LP (€11,344 vs €9,326; p p = 0.13). The survival difference was 0.06 years (p = 0.67), yielding an ICER of €20,387 per life-year gained. Bootstrap analysis indicated a 70% probability of cost-effectiveness at a €35,000 per life-year threshold.
In both device eligible patients, leadless pacemakers showed favorable procedural and clinical outcomes with comparable long-term costs, supporting their cost-effective use in real-world French hospital practice.
What is already known
Leadless pacemakers (LPs) were developed to overcome complications associated with conventional single-lead transvenous pacemakers (SLPs), such as pocket infection, lead dislodgement, and pneumothorax.
LPs have demonstrated lower complication and reintervention rates, as well as improved long-term survival in high-risk populations (e.g. dialysis or post–lead extraction patients).
Despite these advantages, their higher initial cost has limited widespread adoption, particularly among patients eligible for both pacing system

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.31942377.v1（source: https://tandf.figshare.com/articles/dataset/Cost-effectiveness_of_leadless_versus_transvenous_single-chamber_ventricular_pacing_a_propensity-weighted_real-world_study_in_France/31942377）。